Literature DB >> 2549654

Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans.

G M Vogel1, D G Meuleman, F G Bourgondiën, P M Hobbelen.   

Abstract

Two experimental thrombosis models in rats have been compared with regard to the composition of the formed thrombi and the effects of various treatments on thrombus formation. In the first model thrombosis is induced in the vena cava by a combination of venous stasis and hypercoagulability; these thrombi consist merely of red cells and fibrin with only a few platelets. In the second model thrombosis is induced in an arterio-venous shunt in which the formed thrombi consist of red cells, fibrin and a large amount of platelet aggregates adhering to the foreign material. Antiplatelet serum and acetylsalicylic acid, which reduce blood platelet activity, inhibited thrombus formation only in the arteriovenous shunt model. Dicumoxane, an oral anticoagulant, was active in both models. The glycosaminoglycans heparin, Org 10172, Fragmin and the pentasaccharide, representing the AT-III binding sequence of heparin, were active in both models. However, there were qualitative and quantitative differences between the effects of the glycosaminoglycans suggesting differences in their modes of action.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549654     DOI: 10.1016/0049-3848(89)90210-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade.

Authors:  Rômulo A Nazareth; Luana S Tomaz; Susana Ortiz-Costa; Geórgia C Atella; José M C Ribeiro; Ivo M B Francischetti; Robson Q Monteiro
Journal:  Thromb Haemost       Date:  2006-07       Impact factor: 5.249

2.  Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy.

Authors:  Anne Angelillo-Scherrer; Laurent Burnier; Nathalie Flores; Pierre Savi; Maria DeMol; Paul Schaeffer; Jean-Marc Herbert; Greg Lemke; Stephen P Goff; Glenn K Matsushima; H Shelton Earp; Christian Vesin; Marc F Hoylaerts; Stéphane Plaisance; Désiré Collen; Edward M Conway; Bernhard Wehrle-Haller; Peter Carmeliet
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

Review 3.  Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 4.  Animal models of venous thrombosis.

Authors:  Hassan Albadawi; Avery A Witting; Yash Pershad; Alex Wallace; Andrew R Fleck; Peter Hoang; Ali Khademhosseini; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

5.  Isolation and characterization of a heparin with low antithrombin activity from the body of Styela plicata (Chordata-Tunicata). Distinct effects on venous and arterial models of thrombosis.

Authors:  Joana C Santos; Juliana M F Mesquita; Celso L R Belmiro; Carolina B M da Silveira; Christian Viskov; Pierre A Mourier; Mauro S G Pavão
Journal:  Thromb Res       Date:  2007-05-04       Impact factor: 3.944

6.  Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.

Authors:  Elisabeth Perzborn; Stefan Heitmeier; Volker Laux
Journal:  J Cardiovasc Pharmacol Ther       Date:  2015-04-06       Impact factor: 2.457

7.  MARTX toxin of Vibrio vulnificus induces RBC phosphatidylserine exposure that can contribute to thrombosis.

Authors:  Han Young Chung; Yiying Bian; Kyung-Min Lim; Byoung Sik Kim; Sang Ho Choi
Journal:  Nat Commun       Date:  2022-08-17       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.